NasdaqGS:ABCLLife Sciences
Is AbCellera (ABCL) Quietly Recasting Its Platform As A Menopause-Focused Drug Developer?
AbCellera Biologics Inc. recently reported that it has begun dosing patients in the Phase 2 portion of its Phase 1/2 trial for ABCL635, a potential first-in-class non-hormonal treatment for moderate-to-severe menopausal vasomotor symptoms in 80 postmenopausal women.
This marks the first clinical advancement from AbCellera’s GPCR and ion channel platform, highlighting how the company is moving its technology beyond discovery into internally owned therapies targeting menopause-related hot...